Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts' Corner
NEW YORK, December 13, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Teleflex Incorporated (NYSE: TFX), Orexigen Therapeutics, Inc. (NASDAQ: OREX), Sangamo Biosciences, Inc. (NASDAQ: SGMO), InterMune, Inc. (NASDAQ: ITMN), and ImmunoGen, Inc. (NASDAQ: IMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Teleflex Incorporated Research Report
On December 10, 2013, Teleflex Incorporated (Teleflex) announced the agenda for its investor and analyst day meeting, to be held on December 17, 2013. The Company informed that registration will open at 8:30 a.m. ET, along with product displays. The Company noted that the meeting will include presentations, from 9:00 a.m. ET to 12:00 p.m. ET, by Teleflex Chairman, President and CEO Benson Smith and Executive Vice President and CFO Thomas Powell, as well as presentations and Q&A with members of the senior management team, and the Company will host a simultaneous webcast of these presentations. The Full Research Report on Teleflex Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Orexigen Therapeutics, Inc. Research Report
On December 6, 2013, Orexigen Therapeutics, Inc. (Orexigen) announced the closing of its offering of $115 million aggregate principal amount of convertible senior notes due 2020. The Company informed that the Notes bear interest semi-annually at a rate of 2.75% per year, with maturity date of December 1, 2020. Orexigen expects net proceeds from the offering of $110.5 million after deducting the initial purchasers' discounts and commissions and the estimated offering expenses payable by it. The Company intends to use the net proceeds for working capital and other general corporate purposes. The Full Research Report on Orexigen Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Sangamo Biosciences, Inc. Research Report
On December 10, 2013, Sangamo Biosciences, Inc. (Sangamo) announced new pre-clinical data that demonstrated therapeutic levels of gene modification in non-human primates (NHPs) from its In Vivo Protein Replacement Platform. The Company reported that data were presented at the 55th Annual Meeting of the American Society of Hematology. "These data provide proof of concept for this broadly applicable genome editing strategy by demonstrating that our process is scalable to large animals and by validating the use of the albumin safe harbor as a site for expression of therapeutic proteins," said Philip Gregory, D. Phil., Vice President of Research and Chief Scientific Officer at Sangamo. "We have further optimized Sangamo's ZFN system and demonstrated that a single systemic treatment enables stable liver-specific production of replacement protein. Early data in primates suggest that we can achieve circulating levels of protein above the threshold for therapeutic effect, which we believe are sufficient for the correction of a range of monogenic diseases. Our data demonstrate expression of replacement enzymes for multiple different proteins, including those deficient in lysosomal storage disorders, which serves to demonstrate the potential of this approach for a broad range of other monogenic diseases." The Full Research Report on Sangamo Biosciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
InterMune, Inc. Research Report
On December 10, 2013, InterMune, Inc. (InterMune) announced its support of the Pulmonary Fibrosis Foundation to establish the Pulmonary Fibrosis Foundation Care Center Network and Patient Registry. The Company reported that it expects to launch the Care Center Network in 2014 with nine prestigious academic medical centers implementing a care center model that combines high-quality patient care with clinical research in order to collect essential information from patients to build the Registry. "InterMune has spent more than a decade committed to advancing the science of idiopathic pulmonary fibrosis (IPF) - the most prevalent form of pulmonary fibrosis. As part of our ongoing commitment, we are proud to support the Pulmonary Fibrosis Foundation to establish its Care Center Network and Patient Registry. InterMune's vision is to alter the course of IPF - a challenging and deadly disease - through the development of new therapies that can provide hope to patients and their families. We believe this work the Foundation is undertaking is a significant step towards benefiting the IPF community," said Dan Welch, Chairman, CEO and President of InterMune. The Full Research Report on InterMune, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
ImmunoGen, Inc. Research Report
On December 9, 2013, ImmunoGen, Inc. (ImmunoGen) announced clinical findings with SAR3419 (coltuximab ravtansine) used in combination with Rituxan (rituximab) to treat diffuse large B-cell lymphoma (DLBCL), which previously had been treated with standard therapies. According to the Company, a total of 52 patients received SAR3419 and Rituxan in the trial, of which 45 were evaluable for efficacy. Further, according to ImmunoGen, the data demonstrates that the combination of SAR3419 and Rituxan was generally well tolerated, with no patients discontinuing therapy due to treatment emergent adverse events (TEAEs). The Full Research Report on ImmunoGen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.